{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:19:49Z","timestamp":1781612389254,"version":"3.54.5"},"reference-count":34,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T00:00:00Z","timestamp":1705190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstracts<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Metabolic disturbances are major contributors to the onset and progression of non-alcoholic fatty liver disease (NAFLD), which includes a histological spectrum ranging from single steatosis (SS) to non-alcoholic steatohepatitis (NASH). This study aimed to identify serum metabolites and lipids enriched in different histological stages of NAFLD and to explore metabolites\/lipids as non-invasive biomarkers in risk prediction of NAFLD and NASH in obese Chinese.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum samples and liver biopsies were obtained from 250 NAFLD subjects. Untargeted metabolomic and lipidomic profiling were performed using Liquid Chromatography-Mass Spectrometry. Significantly altered metabolites and lipids were identified by MaAsLin2. Pathway enrichment was conducted with MetaboAnalyst and LIPEA. WGCNA was implemented to construct the co-expression network. Logistic regression models were developed to classify different histological stages of NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 263 metabolites and 550 lipid species were detected in serum samples. Differential analysis and pathway enrichment analysis revealed the progressive patterns in metabolic mechanisms during the transition from normal liver to SS and to NASH, including N-palmitoyltaurine, tridecylic acid, and branched-chain amino acid signaling pathways. The co-expression network showed a distinct correlation between different triglyceride and phosphatidylcholine species with disease severity. Multiple models classifying NAFLD versus normal liver and NASH versus SS identified important metabolic features associated with significant improvement in disease prediction compared to conventional clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Different histological stages of NAFLD are enriched with distinct sets of metabolites, lipids, and metabolic pathways. Integrated algorithms highlight the important metabolic and lipidomic features for diagnosis and staging of NAFLD in obese individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.csbj.2024.01.007","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T04:26:30Z","timestamp":1705724790000},"page":"791-800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in Obese Chinese"],"prefix":"10.34133","volume":"23","author":[{"given":"Jiarui","family":"Chen","sequence":"first","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Leibniz Insitute for Natural Product Research and Infection Biology, Microbiome Dynamics, Hans Kn\u00f6ll Institute, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald Siyi","family":"Lu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candela","family":"Diaz-Canestro","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfei","family":"Song","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Department of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Jia","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunchuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia K.Y.","family":"Cheung","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Panagiotou","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Leibniz Insitute for Natural Product Research and Infection Biology, Microbiome Dynamics, Hans Kn\u00f6ll Institute, Jena, Germany"},{"name":"Friedrich Schiller University, Faculty of Biological Sciences, Jena, Germany"},{"name":"Cluster of Excellence Balance of the Microverse, Friedrich-Schiller-University Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region"},{"name":"Department of Pharmacology and Pharmacy, the University of Hong Kong, Hong Kong Special Administrative Region"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"key":"e_1_4_2_2_2","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","author":"Quek J.","year":"2022","unstructured":"Quek J. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis Lancet Gastroenterol Hepatol 2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_4_2_3_2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N.","year":"2018","unstructured":"ChalasaniN.The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology67201832835728714183","journal-title":"Hepatology"},{"key":"e_1_4_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23594"},{"key":"e_1_4_2_5_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Sumida Y.","year":"2014","unstructured":"SumidaY.NakajimaA.ItohY.Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitisWorld J Gastroenterol: WJG20201447524574716","journal-title":"World J Gastroenterol: WJG"},{"key":"e_1_4_2_6_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020117-043617"},{"key":"e_1_4_2_7_2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam M.","year":"2020","unstructured":"EslamM.A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJ Hepatol73202020220932278004","journal-title":"J Hepatol"},{"key":"e_1_4_2_8_2","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella M.E.","year":"2023","unstructured":"Rinella M.E. A multi-society Delphi consensus statement on new fatty liver disease nomenclature Ann Hepatol 2023 101133","journal-title":"Ann Hepatol"},{"key":"e_1_4_2_9_2","first-page":"835","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature reviews Gastroenterology &","volume":"18","author":"Masoodi M.","year":"2021","unstructured":"Masoodi M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature reviews Gastroenterology & hepatology 18 2021 835 856","journal-title":"hepatology"},{"key":"e_1_4_2_10_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","article-title":"Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)","volume":"79","author":"Noureddin M.","year":"2024","unstructured":"NoureddinM.Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)Hepatology79202413514837505221","journal-title":"Hepatology"},{"key":"e_1_4_2_11_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5604\/01.3001.0012.7906","article-title":"Metabolomics discloses a new non-invasive method for the diagnosis and prognosis of patients with alcoholic hepatitis","volume":"18","author":"Michelena J.","year":"2019","unstructured":"MichelenaJ.Metabolomics discloses a new non-invasive method for the diagnosis and prognosis of patients with alcoholic hepatitisAnn Hepatol18201914415431113584","journal-title":"Ann Hepatol"},{"key":"e_1_4_2_12_2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep4.1188","article-title":"Metabolomic\u2010based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts","volume":"2","author":"Mayo R.","year":"2018","unstructured":"MayoR.Metabolomic\u2010based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohortsHepatol Commun2201880782030027139","journal-title":"Hepatol Commun"},{"key":"e_1_4_2_13_2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2021.04.013","article-title":"Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis","volume":"75","author":"Ooi G.J.","year":"2021","unstructured":"OoiG.J.Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitisJ Hepatol75202152453533887358","journal-title":"J Hepatol"},{"key":"e_1_4_2_14_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/MCG.0b013e3181dd1348","article-title":"Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease","volume":"45","author":"Juluri R.","year":"2011","unstructured":"JuluriR.Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver diseaseJ Clin Gastroenterol452011555820505526","journal-title":"J Clin Gastroenterol"},{"key":"e_1_4_2_15_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa P.","year":"2014","unstructured":"BedossaP.Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver diseaseHepatology60201456557524753132","journal-title":"Hepatology"},{"key":"e_1_4_2_16_2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep4.1188","article-title":"Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts","volume":"2","author":"Mayo R.","year":"2018","unstructured":"MayoR.Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohortsHepatol Commun2201880782030027139","journal-title":"Hepatol Commun"},{"key":"e_1_4_2_17_2","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1038\/oby.2007.334","article-title":"The use of BMI and waist circumference as surrogates of body fat differs by ethnicity","volume":"15","author":"Lear S.A.","year":"2007","unstructured":"Lear S.A. Humphries K.H. Kohli S. Birmingham C.L. The use of BMI and waist circumference as surrogates of body fat differs by ethnicity Obes (Silver Spring) 15 2007 2817 2824","journal-title":"Obes (Silver Spring)"},{"key":"e_1_4_2_18_2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/hep.22350","article-title":"Visceral fat: a key mediator of steatohepatitis in metabolic liver disease","volume":"48","author":"van der Poorten D.","year":"2008","unstructured":"van der PoortenD.Visceral fat: a key mediator of steatohepatitis in metabolic liver diseaseHepatology48200844945718627003","journal-title":"Hepatology"},{"key":"e_1_4_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.024"},{"key":"e_1_4_2_20_2","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/oby.22627","article-title":"Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis","volume":"27","author":"Chen J.","year":"2019","unstructured":"Chen J. Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis Obes (Silver Spring) 27 2019 2055 2066","journal-title":"Obes (Silver Spring)"},{"key":"e_1_4_2_21_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000282095","article-title":"PTEN in non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and cancer","volume":"28","author":"Peyrou M.","year":"2010","unstructured":"PeyrouM.BourgoinL.FotiM.PTEN in non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and cancerDig Dis28201023624620460918","journal-title":"Dig Dis"},{"key":"e_1_4_2_22_2","first-page":"248","article-title":"Omega-3 fatty acids and metabolic partitioning of fatty acids within the liver in the context of nonalcoholic fatty liver disease","volume":"25","author":"Calder P.C.","year":"2022","unstructured":"CalderP.C.Omega-3 fatty acids and metabolic partitioning of fatty acids within the liver in the context of nonalcoholic fatty liver diseaseCurr Opin Clin Nutr Metab Care25202224825535762160","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"e_1_4_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2020.02.025"},{"key":"e_1_4_2_24_2","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.febslet.2013.06.019","article-title":"Elevated citrate levels in non-alcoholic fatty liver disease: the potential of citrate to promote radical production","volume":"587","author":"van de Wier B.","year":"2013","unstructured":"van de WierB.Elevated citrate levels in non-alcoholic fatty liver disease: the potential of citrate to promote radical productionFEBS Lett58720132461246623792160","journal-title":"FEBS Lett"},{"key":"e_1_4_2_25_2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.25630","article-title":"Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis","volume":"56","author":"Tanaka N.","year":"2012","unstructured":"TanakaN.MatsubaraT.KrauszK.W.PattersonA.D.GonzalezF.J.Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitisHepatology56201211812922290395","journal-title":"Hepatology"},{"key":"e_1_4_2_26_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hep.29465","article-title":"Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance","volume":"67","author":"Gaggini M.","year":"2018","unstructured":"GagginiM.Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistanceHepatology67201814515828802074","journal-title":"Hepatology"},{"key":"e_1_4_2_27_2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.17219\/acem\/104542","article-title":"Branched chain amino acids: Passive biomarkers or the key to the pathogenesis of cardiometabolic diseases?","volume":"28","author":"Siomkajlo M.","year":"2019","unstructured":"SiomkajloM.DaroszewskiJ.Branched chain amino acids: Passive biomarkers or the key to the pathogenesis of cardiometabolic diseases?Adv Clin Exp Med2820191263126931430068","journal-title":"Adv Clin Exp Med"},{"key":"e_1_4_2_28_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2012.11.026","article-title":"N-Acyl taurines trigger insulin secretion by increasing calcium flux in pancreatic beta-cells","volume":"430","author":"Waluk D.P.","year":"2013","unstructured":"WalukD.P.VielfortK.DerakhshanS.AroH.HuntM.C.N-Acyl taurines trigger insulin secretion by increasing calcium flux in pancreatic beta-cellsBiochem Biophys Res Commun4302013545923159632","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_4_2_29_2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01740-2016","article-title":"Metabolomics analysis identifies different metabotypes of asthma severity","volume":"49","author":"Reinke S.N.","year":"2017","unstructured":"Reinke S.N. Metabolomics analysis identifies different metabotypes of asthma severity Eur Respir J 49 2017","journal-title":"Eur Respir J"},{"key":"e_1_4_2_30_2","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165469","article-title":"Medium-chain fatty acids suppress lipotoxicity-induced hepatic fibrosis via the immunomodulating receptor GPR84","volume":"8","author":"Ohue-Kitano R.","year":"2023","unstructured":"Ohue-Kitano R. Medium-chain fatty acids suppress lipotoxicity-induced hepatic fibrosis via the immunomodulating receptor GPR84 JCI Insight 8 2023","journal-title":"JCI Insight"},{"key":"e_1_4_2_31_2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert J.E.","year":"2014","unstructured":"LambertJ.E.Ramos\u2013RomanM.A.BrowningJ.D.ParksE.J.Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver diseaseGastroenterology146201472673524316260","journal-title":"Gastroenterology"},{"key":"e_1_4_2_32_2","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/hep.23229","article-title":"The plasma lipidomic signature of nonalcoholic steatohepatitis","volume":"50","author":"Puri P.","year":"2009","unstructured":"PuriP.The plasma lipidomic signature of nonalcoholic steatohepatitisHepatology5020091827183819937697","journal-title":"Hepatology"},{"key":"e_1_4_2_33_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/hep.29039","article-title":"Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis in mice","volume":"66","author":"Jang J.E.","year":"2017","unstructured":"JangJ.E.Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis in miceHepatology66201741643128073164","journal-title":"Hepatology"},{"key":"e_1_4_2_34_2","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1007\/s00125-013-2981-2","article-title":"Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids","volume":"56","author":"Oresic M.","year":"2013","unstructured":"OresicM.Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipidsDiabetologia5620132266227423824212","journal-title":"Diabetologia"},{"key":"e_1_4_2_35_2","article-title":"Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid","volume":"12","author":"Yoo W.","year":"2017","unstructured":"Yoo W. Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid PLoS One 12 2017 e0189965","journal-title":"PLoS One"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037024000072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037024000072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2024.01.007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T22:19:33Z","timestamp":1778278773000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2024.01.007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":34,"alternative-id":["10.1016\/j.csbj.2024.01.007"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2024.01.007","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in Obese Chinese","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2024.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}